COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies
This Special Issue aims to dismantle the mechanisms and molecular pathways underlying COVID-19-induced coagulopathy, and present the current advances made possible by our colleagues’ research. The 15 published paper contributions encompassed molecular recruitment and binding, enzymatic dynamics and...
Guardat en:
| Format: | Online |
|---|---|
| Idioma: | anglès |
| Publicat: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Matèries: | |
| Accés en línia: | ONIX_20240514_9783725809646_538 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869523450722254848 |
|---|---|
| collection | Directory of Open Access Books |
| description | This Special Issue aims to dismantle the mechanisms and molecular pathways underlying COVID-19-induced coagulopathy, and present the current advances made possible by our colleagues’ research. The 15 published paper contributions encompassed molecular recruitment and binding, enzymatic dynamics and hemostasis disorders, as well as imagistic high-risk identifiers among the coronary disease population affected by the virus, the connection between psychiatric patients also affected and the thrombosis risk of their antipsychotic therapy, and complications in pediatric patients, along with those with primary and secondary immune disorders. As underlined by the published papers, this Special Issue has brought important contributions in understanding the root mechanisms of SARS-CoV-2-induced coagulopathy, defining diagnostic and prognostic biomarkers, and establishing the role of anti-coagulant and anti-thrombotic therapies which are the most effective for this complex disease. We are pleased to acknowledge that researchers from various fields came together in an effort to provide necessary data about the many forms and manifestations of the coagulations disorders challenging the medical community since the early stages of the pandemic. These data can represent a basis for further studies and a fertile ground for later developments. |
| format | Online |
| id | doab-20.500.12854ir-137923 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1379232024-05-14T14:57:30Z COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies Schiopu, Alexandru Arbănași, Emil Marian Russu, Eliza acute pancreatitis COVID-19 HLA-DR monocytes immune response immunosuppression thrombosis coagulopathy vasculopathy inflammation diabetes mellitus post-acute COVID-19 syndrome fibrinolysis vascular inflammation fat attenuation index plaque vulnerability chronic coronary syndrome pericoronary adipose tissue pulmonary thrombosis SARS-CoV-2 neonatal thrombosis COVID-19 complications bacterial infection platelet activation sCLEC-2 hypofibrinolytic state disorder of immunity cancer COVID-19 infection endothelial dysfunction citokine storm anticoagulant therapy RNase 1 kidney injury biomarker SARS-CoV-2 spike proteins human lung endothelial cells neutrophils P-selectin von willebrand factor IL-6 citrullinated histone H3 neutrophils extracellular traps TFPI DTNB thrombomodulin viscoelastometry hypercoagulable state venous thromboembolism obesity cardiovascular diseases stroke severity spike protein sialic acid glycophorin A hemagglutination hemagglutinin esterase antipsychotic medications n/a thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology This Special Issue aims to dismantle the mechanisms and molecular pathways underlying COVID-19-induced coagulopathy, and present the current advances made possible by our colleagues’ research. The 15 published paper contributions encompassed molecular recruitment and binding, enzymatic dynamics and hemostasis disorders, as well as imagistic high-risk identifiers among the coronary disease population affected by the virus, the connection between psychiatric patients also affected and the thrombosis risk of their antipsychotic therapy, and complications in pediatric patients, along with those with primary and secondary immune disorders. As underlined by the published papers, this Special Issue has brought important contributions in understanding the root mechanisms of SARS-CoV-2-induced coagulopathy, defining diagnostic and prognostic biomarkers, and establishing the role of anti-coagulant and anti-thrombotic therapies which are the most effective for this complex disease. We are pleased to acknowledge that researchers from various fields came together in an effort to provide necessary data about the many forms and manifestations of the coagulations disorders challenging the medical community since the early stages of the pandemic. These data can represent a basis for further studies and a fertile ground for later developments. 2024-05-14T14:57:25Z 2024-05-14T14:57:25Z 2024 book ONIX_20240514_9783725809646_538 9783725809646 9783725809639 https://directory.doabooks.org/handle/20.500.12854/137923 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/9187 https://mdpi.com/books/pdfview/book/9187 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-0963-9 10.3390/books978-3-7258-0963-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725809646 9783725809639 258 open access |
| spellingShingle | acute pancreatitis COVID-19 HLA-DR monocytes immune response immunosuppression thrombosis coagulopathy vasculopathy inflammation diabetes mellitus post-acute COVID-19 syndrome fibrinolysis vascular inflammation fat attenuation index plaque vulnerability chronic coronary syndrome pericoronary adipose tissue pulmonary thrombosis SARS-CoV-2 neonatal thrombosis COVID-19 complications bacterial infection platelet activation sCLEC-2 hypofibrinolytic state disorder of immunity cancer COVID-19 infection endothelial dysfunction citokine storm anticoagulant therapy RNase 1 kidney injury biomarker SARS-CoV-2 spike proteins human lung endothelial cells neutrophils P-selectin von willebrand factor IL-6 citrullinated histone H3 neutrophils extracellular traps TFPI DTNB thrombomodulin viscoelastometry hypercoagulable state venous thromboembolism obesity cardiovascular diseases stroke severity spike protein sialic acid glycophorin A hemagglutination hemagglutinin esterase antipsychotic medications n/a thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies |
| title | COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies |
| title_full | COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies |
| title_fullStr | COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies |
| title_full_unstemmed | COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies |
| title_short | COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies |
| title_sort | covid 19 coagulopathy advances on pathophysiology and therapies |
| topic | acute pancreatitis COVID-19 HLA-DR monocytes immune response immunosuppression thrombosis coagulopathy vasculopathy inflammation diabetes mellitus post-acute COVID-19 syndrome fibrinolysis vascular inflammation fat attenuation index plaque vulnerability chronic coronary syndrome pericoronary adipose tissue pulmonary thrombosis SARS-CoV-2 neonatal thrombosis COVID-19 complications bacterial infection platelet activation sCLEC-2 hypofibrinolytic state disorder of immunity cancer COVID-19 infection endothelial dysfunction citokine storm anticoagulant therapy RNase 1 kidney injury biomarker SARS-CoV-2 spike proteins human lung endothelial cells neutrophils P-selectin von willebrand factor IL-6 citrullinated histone H3 neutrophils extracellular traps TFPI DTNB thrombomodulin viscoelastometry hypercoagulable state venous thromboembolism obesity cardiovascular diseases stroke severity spike protein sialic acid glycophorin A hemagglutination hemagglutinin esterase antipsychotic medications n/a thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology |
| topic_facet | acute pancreatitis COVID-19 HLA-DR monocytes immune response immunosuppression thrombosis coagulopathy vasculopathy inflammation diabetes mellitus post-acute COVID-19 syndrome fibrinolysis vascular inflammation fat attenuation index plaque vulnerability chronic coronary syndrome pericoronary adipose tissue pulmonary thrombosis SARS-CoV-2 neonatal thrombosis COVID-19 complications bacterial infection platelet activation sCLEC-2 hypofibrinolytic state disorder of immunity cancer COVID-19 infection endothelial dysfunction citokine storm anticoagulant therapy RNase 1 kidney injury biomarker SARS-CoV-2 spike proteins human lung endothelial cells neutrophils P-selectin von willebrand factor IL-6 citrullinated histone H3 neutrophils extracellular traps TFPI DTNB thrombomodulin viscoelastometry hypercoagulable state venous thromboembolism obesity cardiovascular diseases stroke severity spike protein sialic acid glycophorin A hemagglutination hemagglutinin esterase antipsychotic medications n/a thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology |
| url | ONIX_20240514_9783725809646_538 |